ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

PTC Therapeutics and Biogen side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

PTC TherapeuticsBiogen
studies on the registry72549
open to participants now328
phase 3 studies under way319
reach primary completion within a year115
programswith a study of their own in two years211

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phasePTC TherapeuticsBiogen
Phase 100%

Biogen: 3 of its 11 programs at phase 1

  1. BIIB142phase 1
  2. BIIB144phase 1
  3. BIIB145phase 1
27%
Phase 2

PTC Therapeutics: 1 of its 2 programs at phase 2

  1. PTC844phase 2
50%

Biogen: 1 of its 11 programs at phase 2

  1. BIIB147phase 2
9%
Phase 3

PTC Therapeutics: 1 of its 2 programs at phase 3

  1. alpha-tocotrienol quinonephase 3
50%

Biogen: 5 of its 11 programs at phase 3

  1. felzartamabphase 3
  2. pegcetacoplanphase 3
  3. salanersenphase 3
  4. omaveloxolonephase 3
  5. diroximel fumaratephase 3
45%
Approved, new studies00%

Biogen: 2 of its 11 programs at approved, new studies

  1. tofersenapproved, new study
  2. Dimethyl Fumarateapproved, new study
18%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
PTC Therapeutics1 readouts · 0 phase 3··········

PTC Therapeutics, Sep ’27: 1 program whose next study reaches primary completion

  1. PTC844phase 2 · Sep 30 · NCT07779616
·
Biogen4 readouts · 2 phase 3·

Biogen, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. felzartamabphase 3 · Dec 1 · NCT06685757
·

Biogen, Feb ’27: 1 program whose next study reaches primary completion

  1. BIIB145phase 1 · Feb 2 · NCT07225517
··

Biogen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tofersenapproved, new study · May 26 · NCT07223723

Biogen, Jun ’27: 1 program whose next study reaches primary completion

  1. pegcetacoplanphase 3 · Jun 25 · NCT07215390
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

PTC Therapeutics

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Biogen

New programs 1

  • BIIB147phase 2 · first study · Sep 28 · Amyotrophic Lateral Sclerosis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionPTC TherapeuticsBiogen
Arthritis, Rheumatoidboth · compare here

PTC Therapeutics in Arthritis, Rheumatoid: 1 program

  1. PTC844phase 2

Their studies: PTC Therapeutics’ studies of Arthritis, Rheumatoid in search

Biogen in Arthritis, Rheumatoid: 1 program

  1. Dimethyl Fumarateapproved, new study

Their studies: Biogen’s studies of Arthritis, Rheumatoid in search

Friedreich Ataxiaboth · compare here

PTC Therapeutics in Friedreich Ataxia: 1 program

  1. alpha-tocotrienol quinonephase 3

Their studies: PTC Therapeutics’ studies of Friedreich Ataxia in search

Biogen in Friedreich Ataxia: 1 program

  1. omaveloxolonephase 3

Their studies: Biogen’s studies of Friedreich Ataxia in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: PTC Therapeutics 1 of 2 · Biogen 5 of 11 programs (6 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.